The key changes for the new 2025 EULAR recommendations on RA treatment #EULAR2025 @RheumNow https://t.co/dp5LnoFdpW

• https://x.com/drdavidliew/status/1933801766572728598/photo/1

#EULAR new #RA #recommendations J Smolen presents justification for #MTX +#glucocorticoids at onset do you agree? Diff from #ACR #EULAR #Recommendations II #EULAR2025 @RheumNow https://t.co/wqCX5HA87q

• https://x.com/Janetbirdope/status/1933802206576435494/photo/1

URAT1 inhibitors look like the way to go in Gout! Presented in multiple abstracts at #EULAR2025 Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300 Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302 Ph 2b RCT of SAP-001 Refractory Gout +/-

EULAR Points to consider for the definition of #D2M #Psoriatic_Arthritis 1️⃣ Failure >= 2 b/tsDMARDs with >=2 different MOA 2️⃣ Perceived as problematic 3️⃣ Evidence of persistent disease (active disease, EMM, inflammation) #EULAR2025 @RheumNow https://t.co/69nFEYntF0

• https://x.com/Nellziade/status/1933803800533340267/photo/1

EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis #D2M 1️⃣ Failure >= 2 b/tsDMARDs 2️⃣ Problematic 3️⃣ Evidence of persistent disease (inflammation is mandatory) + 4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI #EULAR2025 @RheumNow https://t.co/8nx26mWX3C

• https://x.com/Nellziade/status/1933804987077066881/photo/1

@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains. Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for #EULAR2025 @RheumNow https://t.co/fIxHRGDFcK

• https://x.com/drdavidliew/status/1933805119688040593/photo/1
• https://x.com/drdavidliew/status/1933805119688040593/photo/1
• https://x.com/drdavidliew/status/1933805119688040593/photo/1
• https://x.com/drdavidliew/status/1933805119688040593/photo/1

Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA: ✅ ACR20: 54% vs 34% (placebo) ✅ Skin, joints, fatigue, QoL 📉 Post hoc: less radiographic progression No new safety signals at W16. LB0001 @RheumNow #EULAR2025

📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA. Also improved QoL, skin, and MSK outcomes. Post hoc: slowed radiographic progression. Well tolerated & no new safety signals @RheumNow #EULAR2025 #LB0001

📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT. ASAS20: 51% vs 9%; ASAS40: 23% vs 3%. Promising app-based intervention comprising individualised exercise, pt education & disease Mx. @RheumNow #EULAR2025 #LB0002

from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE So far so good but how far do we need to go? #EULAR2025 @RheumNow LB0007

Older adults with chronic MSK pain report lower physical health—but better mental health—than younger peers. Fewer missed work days, too. Is this resilience, adaptation, or shifting expectations with age? POS0402 @RheumNow #EULAR2025

#EULAR2025 Abstr#LB0001 Phase 3 RCT of Deucravacitinib in psoriatic arthritis met endpoints (ACR20) over PBO at Week 16. Prespecified early radiographic was not significant but post-hoc (without imputed data) showed radiographic inhibition @RheumNow https://t.co/ORUBtUWH31

• https://x.com/Yuz6Yusof/status/1933808337579061454/photo/1

#EULAR2025 @eular_org update #Recommendations #Rheumatoid #Rx prof Smolen subtle diff between former guidelines MTX+GC 👇 D/C GCs rapidly 👇 If inadequate response 👇 Other csDMARDs are OUT ❎ ✅go to bDMARD or tsDMARD* TsDMARD after safety assessed @RheumNow RecommendatnII https://t.co/yUrLdk6Eg1

• https://x.com/Janetbirdope/status/1933809499317338186/photo/1

Presenteeism and absenteeism in RA aren’t just about joints. In this UK study, comorbid anxiety, depression, and OA drove lost productivity. Treating RA is not enough —holistic management matters. POS0403 @RheumNow #EULAR2025

🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID). Acceptable safety profile & tolerability. @RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n

• https://x.com/DrMiniDey/status/1933810894406131908/photo/1